Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and efficacy of HSK44459 Tablets in idiopathic pulmonary fibrosis
CTR20252275Phase 2Active
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HSK44459 in idiopathic pulmonary fibrosis (IPF), sponsored by Haisco Pharmaceutical Group Co., Ltd.. Started Jun 2025; status: active.
02
Drugs
HSK44459
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on CTR20252275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252275.